Related Experiment Videos
[Sentinel lymph node biopsy in breast cancer]
Kunwei Shen1, Lamichhane Nirmal, Qixia Han
1Department of Surgery, Cancer Hospital, Fudan University, Shanghai 200032, China.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]
|July 23, 2002
Summary
Sentinel lymph node biopsy (SLNB) accurately predicts axillary lymph node status in breast cancer patients, with 92.5% accuracy. This method is highly effective for T1 lesions, achieving 100% accuracy in predicting nodal status.
Area of Science:
- Oncology
- Surgical Pathology
Context:
- Accurate staging of breast cancer is crucial for treatment planning.
- Axillary lymph node status is a key prognostic factor.
Purpose:
- To assess the diagnostic accuracy of sentinel lymph node biopsy (SLNB) in determining axillary lymph node involvement in breast cancer.
- To evaluate the clinical significance of SLNB compared to standard axillary dissection.
Summary:
- SLNB successfully identified sentinel lymph nodes in 95.7% of 70 breast cancer patients.
- The overall accuracy of SLNB was 92.5%, with a false-negative rate of 7.5%. Accuracy reached 100% for tumors ≤2 cm.
- Immunohistochemical staining did not improve micrometastasis detection over HE staining.
Impact:
- SLNB provides a reliable method for staging the axilla in breast cancer patients.
- This technique can potentially spare patients from unnecessary axillary dissection, reducing morbidity.
- Findings support the use of SLNB as a standard procedure for early-stage breast cancer.